Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing ; volume:36 ; number:3 ; day:9 ; month:4 ; year:2022 ; pages:373-380 ; date:5.2022
BioDrugs ; 36, Heft 3 (9.4.2022), 373-380, 5.2022
- Creator
-
Akkooi, Alexander C. J. van
Zijlker, Lisanne P.
Wouters, Michel W. J. M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40259-022-00525-x
- URN
-
urn:nbn:de:101:1-2022073008045892578496
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Akkooi, Alexander C. J. van
- Zijlker, Lisanne P.
- Wouters, Michel W. J. M.
- SpringerLink (Online service)
Other Objects (12)
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Predictors of responses to immune checkpoint blockade in advanced melanoma
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation
Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Predictors of responses to immune checkpoint blockade in advanced melanoma
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation
Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Predictors of responses to immune checkpoint blockade in advanced melanoma
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation